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Abstract: Majocchi’s granuloma (MG) is a rare fungal infection of the dermis that is mainly 
caused by dermatophytes (in ≥95% of cases); the most frequently identified cause is anthropo-
philic Trichophyton rubrum. In the rest of the cases, the causes are non-dermatophytic fungi 
such as Aspergillus species. This review aimed to provide information about the current perspec-
tives on MG regarding its clinical characteristics, predisposing factors, laboratory diagnosis, 
and treatment strategies. Although the lower extremities were reported to be the most common 
site of infection, facial involvement has been predominant in the past 5 years. Our literature 
research showed that the most common predisposing factor (55%) is the use of topical steroid 
creams without potassium hydroxide examination during treatment of erythematous squamous 
dermatoses. A reliable diagnosis of MG is based on histopathological examination, including 
fungal culture and molecular analyses. MG should be treated not only with topical agents 
but also with systemic antifungal agents that are continued until the lesions are completely 
resolved. In systemic treatment, the most preferred drug is terbinafine, because of its efficacy, 
side effects, and safety.
Keywords: dermatomycosis, histopathology, immunosuppression, predisposing factor, Tricho-
phyton rubrum
Introduction
Dermatophytes are highly specialized keratinophilic and keratinolytic fungi that con-
sist of seven genera, including Trichophyton, Microsporum, Epidermophyton, and the 
recently introduced Arthroderma, Paraphyton, Nannizzia, and Lophophyton.1 Although 
dermatophytes are the most common human fungal pathogens worldwide, these fungi 
are neglected because 1) they uncommonly cause a life-threatening disease;2 2) in vitro 
resistance to the first choice of antifungal drugs has been reported, but it is not very 
common;3 and 3) most of the effective antifungal drugs are accessible in most countries.4 
However, besides the ability of these fungi to cause infections in both immunosup-
pressed and immunocompetent individuals, a growing population of individuals with 
diabetes and immunosuppression, improvements in medical device technology, and 
the prolonged life spans of these patients make these fungi more noticeable.5
Majocchi’s granuloma (MG) is an inflammatory and granulomatous, dermatophytic 
infection that is classified into two forms, depending on the affected individual’s health 
situation and clinical picture. The first form is mainly observed in healthy individuals 
and is defined as a perifollicular, papular form induced by penetrating trauma that is 
mostly observed in the lower extremities. The second form is granulomatous, related 
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to immunosuppression, seen in a nodular form, and usually 
appears on the upper extremities.6 The main cause of MG 
is Trichophyton rubrum, followed by T. mentagrophytes, 
T. violaceum, and T. tonsurans. However, several fungi, such 
as T. interdigitale, Microsporum canis, Nannizzia gypsea 
(former M. gypseum), Epidermophyton floccosum, and 
Aspergillus species, can also cause MG.7−10
Throughout our review of the epidemiological charac-
teristics and treatment strategies of MG,11 we noticed that 
the number of cases of MG has been rising over the past 
5 years. In addition, we are aware that there is some confusion 
regarding the classification of this invasive infection. Hence, 
in this review, we aimed to provide up-to-date information 
about the current knowledge on MG, including demographic 
characteristics, clinical features, predisposing factors, and 
diagnostic and treatment strategies for the disease. 
Search strategy
We searched PubMed (MEDLINE) and Google Scholar for 
MG cases that were published in the English-language litera-
ture between August 2011 and November 2017, using the key 
words “Majocchi’s granuloma,” “trichophytic granuloma,” 
and “dermatophytic granuloma.” Other types of invasive or 
disseminated dermatophyte infections were excluded from 
the present review. The clinical and demographic characteris-
tics of 33 patients with MG from 32 articles were evaluated.
Invasive dermatophytosis and MG
Although dermatophytes require keratin for nutrition, in 
some circumstances, they can be isolated from the deeper 
layers of the skin.12−16 In our previous review, we classified 
these infections as follows: 1) MG (nodular, granulomatous 
perifolliculitis); 2) deeper dermal dermatophytosis; 3) dis-
seminated dermatophytosis; and 4) mycetoma and pseudo-
mycetoma (Figure 1).11
Importantly, in the case of dermis invasion by dermato-
phytes, the immune response determines the clinical picture 
as follows: 1) a granulomatous inflammation around the hair 
follicle is called MG. Histopathologically, MG demonstrates 
a nodular perifollicular granulomatous infiltrate of lymphoid 
cells, macrophages, epithelioid cells, multinucleated giant 
cells, and neutrophils. Unlike superficial dermatophytoses, 
fungal hyphae and spores can be detected not only on the 
surface of the epidermis but also within or around the hair 
follicles (Figure 1);16 2) in mycetoma, dermal fungal elements 
are surrounded by an eosinophilic material, including antigen- 
antibody complexes and debris from host inflammatory cells 
(Splendore-Hoeppli reaction); 3) dermal invasion and a mild 
immune response without perifollicular granulomatous 
inflammation or a Splendore-Hoeppli reaction are called deep 
dermal dermatophytosis; 4) the clinical picture that consists 
of vascular involvement and dissemination to other organs is 
called disseminated dermatophytosis (Figure 1). In this latest 
form, fungi can be isolated from sputum, blood, or other tissue 
samples in addition to skin biopsy samples.14,16−18
Recently, Rouzaud et al19 reported the clinical and histo-
logical differences between deep dermatophytosis and MG. 
However, a patient’s immune status, the type and location 
of the lesion, and direct microscopic examination with 
potassium hydroxide (KOH) may not be helpful to reliably 
diagnose MG.
Pathogenesis
Dermatophytes degrade the keratin in nonliving keratinized 
tissues to survive. However, in the case of MG, the fungi must 
survive in the dermal and subcutaneous tissues. Although the 
underlying mechanisms of the pathogenesis of MG are not 
well understood, there are some proposals for this mecha-
nism, and they all rely on several factors that are associated 
with the host and microorganism. 
The first and most important host factor is a physical skin 
barrier that prevents fungal skin infections.20 Physical trauma 
of the skin due to shaving or scratching and immunosup-
pression are believed to cause fungal invasion. This invasion 
occurs because of damage to the epidermal barrier’s integrity 
and follicular disruption; thus, microorganisms, along with 
keratin and necrotic materials, can enter the dermis. Fungi 
must hide from the host’s immune system, and they cause 
an inflammatory response during infection. Fungal LysM 
domain-associated proteins mask chitin on the fungal cell wall 
and regulate fungal growth and development.21 Fungi also 
have several enzymes, such as lipases, esterases, and collage-
nases.22 Moreover, the microorganisms express several genes 
that encode the key components of the glyoxylate pathway 
(i.e. isocitrate lyase and malate synthase) and excrete a large 
amount of sulfite to degrade the components of the skin.23,24
Dermatophytes can cause deep and invasive infections 
under some acquired or congenital immunosuppressive 
conditions. For instance, disseminated dermatophytosis 
might be associated with lymphopenia, reduced complement 
C3 and C4, and hypogammaglobulinemia.25 Additionally, 
the deficiency of autosomal-recessive caspase recruitment 
domain-containing protein 9, which has effects on the signal 
transducer and activator of the transcription 3 pathway and 
interleukin (IL)-17 and IL-22 secretion, was also reported 
in 17 patients with deep dermatophytosis.26−28
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Host factors also affect the characteristics of the infec-
tion. In a patient with pancytopenia, dermal dermatophytosis 
without granuloma- or dermatophyte-related sepsis might 
develop. However, in a patient with partial immunosuppres-
sion, granuloma, abscesses, and mycetoma may occur.12,14 The 
host also uses several mechanisms to control the infection. 
Antimicrobial peptides such as cathelicidins and defensins 
protect the patient against fungi, and they also promote epi-
dermopoiesis to clear the infection.29,30 In addition, natural 
killer cells, neutrophils, and macrophages also respond to 
dermatophytosis. Therefore, therapeutic immunosuppression 
causes lower cellular immunity and ingestion/killing rate of 
fungal spores.31
Source of infection and possible 
predisposing factors
The available data in the literature provide some predictions 
about the source of infection and predisposing factors of 
Figure 1 Pathogenesis of invasive dermatophytosis. 
Notes: Physical trauma impairs the epidermal barrier. Penetration of the dermatophytes into the skin causes a granulomatous, inflammatory response, including neutrophils 
(N), eosinophils (E), lymphocytes (T), macrophages (M), and multinuclear giant cells (MGC). Majocchi’s granuloma (A), mycetoma (B), deeper dermatophytosis (C), and 
disseminated dermatophytosis (D).
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MG. It commonly occurs in the presence of chronic derma-
tophytoses, such as tinea unguium and tinea corporis.13,28,32−36 
These infections may be a source of MG in cases wherein 
the skin barrier is destroyed. Moreover, shaving the legs or 
pubic area, sexual contact, and occupation should also be 
investigated.7,8,37,38 In this review, four of the patients were 
thought to have been in contact with an animal, suggesting 
that animal exposure was a predisposing factor of MG. Three 
of these patients had been in contact with guinea pigs.34,39,40 
Guinea pigs are often cryptic carriers,41 and the clinician 
should consider the zoophilic characteristics of dermato-
phytes and whether the patient has a pet or is in frequent 
contact with animals.
Preexisting dermatophytosis is a major risk factor of MG. 
Consistently, Kershenovich et al42 reported that the anatomic 
regions that are involved in preexisting dermatophytosis are 
the possible origins of MG. This was also evident in our 
review, which reflected that 10/24 immunocompetent and 7/9 
of immunosuppressed patients had prior or concomitant der-
matophytic infections. The lesions that were reported in these 
patients were related to MG, except those in two patients. One 
was an immunocompetent male patient who had lesions on his 
suprapubic and inguinal regions and a tinea barbae as a prior 
dermatophytosis.7 However, the patient had a history of unpro-
tected sexual exposures in Thailand. The other was a healthy 
58-year-old man who had tinea pedis prior to developing MG 
lesions on his left forearm, but the source of infection could not 
be determined because he did not have a history of any local or 
general immunosuppressive conditions or animal exposure.43
Long-term use of steroids, chemotherapy, and antineo-
plastic therapy or other immunosuppressive conditions may 
also lead to MG.32,44−47 In particular, steroids have been used 
successfully to treat many lethal diseases, such as pemphigus. 
However, many cases with steroid use-related sepsis have 
also been recorded. Steroids affect the functions of macro-
phages and neutrophils and reduce the Th1-mediated immune 
response. After steroid use, lesions may become atypical, and 
complete resolution of fungal infections may be delayed.36,48 
Our analyses revealed that the use of steroids (n=21) was the 
most common underlying condition. 
The increase in organ transplantation led to the extensive 
use of some immunosuppressive drugs such as tumor necrosis 
factor alpha inhibitors (e.g. adalimumab). Although these 
drugs can reduce the side effects of steroids, an MG patient 
who had used adalimumab was reported.49 Similarly, BRAF 
inhibitors (e.g. vemurafenib) are considered promising treat-
ments for aggressive skin tumors; however, they may also 
facilitate MG development.32
Dermatophytic infections occur frequently in human 
immunodeficiency virus- or acquired immune deficiency 
syndrome (AIDS)-positive patients; however, there is no 
consensus on whether there is any relationship between 
the lymphocyte count and cutaneous dermatophytosis.50,51 
When it occurs, dermatophytosis can be either atypical 
or widespread in these patients. In addition to invasive 
and chronic, resistant infections, MG can also develop.52 
Among the cases that were searched for in this review, 
only one case with T. tonsurans had AIDS.53 Several other 
possible predisposing factors, such as chemotherapy (n=1) 
and transplantation [solid organ (n=3) and facial tissue 
allotransplantation (n=1)], were also addressed in some 
studies.
Clinical characteristics
The clinical pictures of MG in healthy individuals and 
immunosuppressed patients differ. A perifollicular, papular 
form that is induced by penetrating trauma is mostly seen in 
healthy individuals. On the other hand, the granulomatous 
form is related to immunosuppression and is seen in nodular 
forms.6 In addition to the papular and nodular forms, plaques, 
patches, and multiple forms, with or without a crust, can also 
be seen on the lesions (Figure 2A and B). 
We reviewed 32 studies including 33 cases (21 men and 
12 women) that were published in the English language lit-
erature between August 2011 and November 2017. The mean 
age of the patients was 38 years (range: 3–65 years), and 
the mean duration of the infections was 9 months (range: 3 
days–60 months). The clinical characteristics of patients with 
MG are shown in Figure 3. The majority of the patients in 
Figure 2 Multiple erythematous papules and nodules with scales and/or crusts 
are located on the anterior surface of the abdomen in a patient with Majocchi’s 
granuloma (A). Erythematous plaque with pustules, scales, and crusts on the lateral 
side of the arm in a patient with Majocchi’s granuloma (B).
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both the immunocompetent and immunosuppressed groups 
had multiple lesions: 16/24 and 7/9, respectively. The most 
affected area was the face (37.5%) among all immunocom-
petent patients and the lower extremities among the immu-
nosuppressed patients (66.7%). Although multiple types of 
lesions (n=22) appeared, the most predominant forms were 
nodules (n=19) and plaques (n=19).  Immunocompetent 
patients mostly had plaques (62.5%) and nodules (54.2%), 
whereas immunosuppressed patients had nodules (66.7%) 
and papules (55.6%). In addition, erythroderma and pal-
moplantar hyperkeratosis have been reported in a patient 
with AIDS.53
The number of reported MG cases has increased remark-
ably in the past 6 years (n=33), compared to that between 
Figure 3 Clinical characteristics of the patients with MG reported in the literature: location of the lesions, sex, immunity, predisposing factors, and type of lesion.
Abbreviation: MG, Majocchi’s granuloma.
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1883 and 2011 (n=79). Moreover, the frequency of facial 
involvement was also prominently higher (36.4%) than that 
previously reported (6.3%).11
Laboratory diagnosis
Diagnosing MG requires detection of not only dermatophytes 
but also perifollicular granulomatous inflammation. The most 
commonly used method for displaying fungal hyphae and 
spores is KOH examination (n=18; 7/18 had negative results). 
However, KOH examination is insufficient for distinguishing 
superficial and invasive dermatophytoses. As mentioned pre-
viously, perifollicular granulomatous inflammation should be 
demonstrated for the diagnosis of MG (Figures 4A and B).37 
However, in this review, we noted that a histopathological 
examination was not performed in nine patients with MG. 
Further, in four patients, the staining techniques of histologi-
cal examination were not mentioned.7,28,43,46,54
The stains used in histopathological examinations are 
very important. Although histopathological examination is 
the “gold standard” method for demonstrating granulomatous 
infiltration, hematoxylin-eosin (HE) staining, which is used 
in routine histopathology, may be insufficient in detecting 
fungal elements. The most frequently used staining methods 
for eliminating this deficiency are the periodic acid-Schiff 
(PAS) (n=18) and Grocott-Gomori’s methenamine silver 
(GMS) (n=5) methods.49,54,55
PAS staining is more preferable in the histopathological 
examination of samples containing suspected fungal infec-
tion than GMS because it is easy to perform and has higher 
sensitivity and negative predictive values (Figure 4C).56 
When the fungal elements on the suspected samples are 
numerous, HE staining can also be helpful. However, when 
there are few fungal elements, they may be overlooked.57 HE-
stained preparations can be examined under an immunofluo-
rescence microscope, and fungi are shown as autofluorescent 
particles (Figure 4D).58 On the other hand, GMS staining can 
be more helpful because it has greater contrast than PAS 
staining. However, there are no adequate data to conclude 
that GMS staining is superior to PAS staining. Although 
GMS staining has an advantage over PAS because it has 
better powers of detection on low- and intermediate-power 
microscopy and better contrast to detect fungal  elements 
Figure 4 Histopathological findings of a patient with MG. 
Notes: (A) The histopathology showed perifollicular, granulomatous inflammation (arrows). (B) Hyphae (arrows) are seen with great magnification. (C) Perifollicular spores 
(arrows) were positively stained with PAS staining. (D) In the HE-stained slides, spores (arrows) showed autofluorescence under an immunofluorescence microscope. (A, 
HE ×100; B, D, HE ×1000; C, PAS ×1000). 
Abbreviations: MG, Majocchi’s granuloma; PAS, periodic acid-Schiff staining; HE, hematoxylin and eosin.
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easily, it is time and temperature dependent, requires an 
expert technician, and contains hazardous compounds such 
as chromic acid.56,59,60
As histological examination is not sufficient for the 
identification of a fungus, especially in immunosuppressed 
patients, it is important to use molecular-based techniques, 
such as internal transcribed spacer (ITS) sequencing, for 
identifying fungal species.1,55,61,62 A fungal culture is required 
both to detect fungal pathogens and to recognize the spe-
cies eventually by combining histological analysis and ITS 
sequencing. Among the studies that were reviewed, fungal 
culturing was performed for 28 cases, only 1 of which was 
negative.63 In only seven patients, the isolates were identified 
molecularly using ITS primers. Performing more than one 
technique, that is, culturing and microscopy, almost always 
leads to the detection of fungal elements.10,35,53,64−66
Etiological agents
The causes of dermatophytosis depend on the geographic 
region. Consistently, the etiology of MG may also differ. 
However, T. rubrum is the most isolated fungal agent of MG 
in both immunocompetent and immunosuppressed individu-
als worldwide. Additionally, T. interdigitale, T. tonsurans, 
T. violaceum, M. canis, M. ferrugineum, N. gypsea, and 
E. floccosum were also reported.7,8,10,35,49,66 In this review, the 
most common fungal isolate was T. rubrum (n=15), followed 
by T. mentagrophytes (n=5), T. interdigitale (n=2), N. gypsea 
(n=2), T. tonsurans (n=2), and T. violaceum (n=1) (Table 1). 
Non-dermatophytic fungi such as those belonging to 
the genera Phoma and Aspergillus were also reported as 
etiological agents of MG.9,67 Among the 33 cases that were 
reviewed, only one study reported the presence of a non-
dermatophytic but keratinophilic fungus, a Malbranchea 
species, in an immunocompetent patient who had eczema 
as the underlying disease.68
Differential diagnosis
MG can be confused with diseases that also cause chronic 
erythematous papules and nodules. Due to the presence of 
pain in these lesions, they are usually perceived as symptoms 
of bacterial infections, and this confusion results in patients 
receiving antibiotic treatment. Other chronic infections 
(e.g. mycobacterial infections, deep fungal infections, dis-
seminated toxoplasmosis, and cutaneous leishmaniasis) may 
also be misleading.11 In addition to histopathology, bacterial, 
fungal, and parasitic examinations, as well as polymerase 
chain reaction and other molecular diagnostic tools, are cru-
cial for reliable organism detection. Notably, when the lesion 
involves the face, it can imitate granulomatous rosacea and 
granuloma faciale. Painful nodules also imitate erythema 
nodosum, thrombophlebitis, and erythema induratum bazin. 
In immunosuppressed patients, it is important to distinguish 
MG from some tumoral diseases such as Kaposi sarcoma 
and lymphoma.36
Treatment
Oral potassium iodide, local X-radiation, and topical 
2-dimethylamino-6-(β-diethylaminoethoxy)-benzothiazole 
(Asterol®) were used to treat MG before antifungal treatments 
were discovered. Antifungal drugs are used topically and/or 
systemically. Although topical antifungal therapy is usually 
sufficient for the treatment of superficial dermatophytoses, 
systemic treatment is also required to treat tinea capitis, 
onychomycosis, invasive dermatophytoses, and widespread 
superficial dermatophytoses. The selection of antifungal 
drug changes with the discovery of novel antifungal drugs. 
Although ketoconazole was frequently used previously, 
about half of the patients reported today are treated with 
terbinafine (250 mg/day).8,13,36,40,43,47,54,68−71 Other systemic 
antifungal drugs are itraconazole (100–200 mg/day),32,44,53,72 
griseofulvin (250–500 mg/day),10,35,63 voriconazole,73 and 
posaconazole.28 Antifungal therapy should be continued 
until the lesions are completely resolved. Depending on the 
severity of the disease, the duration of MG treatment varies 
from 1 to 6 months.55,69
Rallis et al37 reported a patient who did not respond 
to systemic itraconazole treatment, but responded well to 
systemic terbinafine treatment. Liu et al73 reported the case 
of a patient with a mixed infection of T. rubrum and Kleb-
siella pneumoniae and treated this case first with systemic 
antibiotics (combined cefoselis and levofloxacin for 7 days) 
and then voriconazole (200 mg, twice daily). Although some 
newer antifungal drugs were developed after terbinafine, 
the interaction of novel antifungal drugs is higher than that 
Table 1 The causative fungi that were isolated from patients with 
MG
Causative fungi Frequency (%)
Dermatophytic fungi 96.4
Trichophyton rubrum 55.6
T. mentagrophytes 18.5
T. interdigitale 7.4
T. tonsurans 7.4
T. violaceum 3.7
Nannizzia gypsea 7.4
Non-dermatophytic fungus 3.6
Malbranchae sp. 3.6
Abbreviation: MG, Majocchi’s granuloma.
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of terbinafine. Post-inflammatory pigmentation, atrophic 
scarring, and alopecia may develop following the use of 
antifungal treatment.7,34,36,37,47,70
Conclusion
MG is an uncommon fungal infection that is mostly related 
to local physical trauma of the skin, followed by disruption 
of the hair follicles. It may occur in both immunosuppressed 
and immunocompetent individuals. The source of MG can 
be a prior dermatophyte infection, exposure to infected 
or asymptomatic animals or humans, and local or general 
immunosuppressive conditions. 
The diagnosis of MG should be verified by histological 
examinations, and PAS or GMS staining reveals evidence of 
the infection. Recognizing the fungal species using conven-
tional and/or molecular methods is also crucial, particularly 
in immunosuppressed patients. Additionally, understanding 
the clinical, epidemiological, and histological characteristics 
of the infection depends on an accurate and reliable clinical 
and mycological diagnosis. MG can mimic several other 
infections; therefore, it is important to differentiate MG 
and begin treatment as soon as possible. Topical antifungal 
agents do not respond to treatment, and systemic antifungal 
agents should be applied at a proper dose and for an appro-
priate duration. Further studies in this field should focus on 
proposing a guideline that includes the current diagnostic 
and management procedures of MG.
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